Dynavax ups revenue guidance

 

• Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase

• Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million

• Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year

• Conference call Thursday at 4:30 p.m. ET/1:30 p.m. PT

2023 FINANCIAL GUIDANCE
Full year 2023 financial guidance has been revised to consist of the following expectations:

• Raising HEPLISAV-B net product revenue between approximately $200 - $215 million, compared to the prior range of approximately $165 - $185 million

• Reiterating research and development expenses between approximately $55 - $70 million

• Reiterating selling, general and administrative expenses between approximately $135 - $155 million

Conference Call and Webcast Information

Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

https://finance.yahoo.com/news/dynavax-reports-second-quarter-2023-200500061.html